PharmaPoint: Hepatitis C Virus - France Drug Forecast and Market Analysis to 2022
Table Of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Prognosis 17
3.2 Symptoms 17
4 Disease Management 18
4.1 Diagnosis and Referral Overview 18
4.2 Treatment Overview 19
4.3 France 22
4.3.1 Diagnosis 22
4.3.2 Clinical Practice 23
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 24
5.3 Product Profiles – Major Brands 26
5.3.1 Incivek (telaprevir) 26
5.3.2 Victrelis (boceprevir) 31
5.3.3 Pegasys (peginterferon alfa-2a) 35
5.3.4 PegIntron (peginterferon alfa-2b) 40
5.3.5 Copegus, Rebetol, and Generic Ribavirin 44
5.3.6 Therapeutic Class: Interferon 46
6 Opportunity and Unmet Need 47
6.1 Overview 47
6.2 Unmet Needs 48
6.2.1 Unmet Need: Treatment Tolerability 48
6.2.2 Unmet Need: Efficacy 48
6.2.3 Unmet Need: Disease Awareness 49
6.2.4 Unmet Need: Treatment Cost 50
6.2.5 Unmet Need: Shorter Treatment Duration 50
6.2.6 Unmet Need: Simplified Treatment Regimens 51
6.3 Unmet Needs Gap Analysis 52
6.4 Opportunities 53
6.4.1 Opportunity: Pan-genotypic HCV Regimen 53
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 53
6.4.3 Opportunity: Involvement of Immune System 54
7 Pipeline Assessment 55
7.1 Overview 55
7.2 Promising Drugs in Clinical Development 56
7.2.1 Sofosbuvir and Sofosbuvir/Ledipasvir 58
7.2.2 Simeprevir 68
7.2.3 ABT-450 plus ABT-267 and ABT-333 76
7.2.4 Faldaprevir and Faldaprevir plus BI 207127 83
7.2.5 Daclatasvir and Daclatasvir plus Asunaprevir 91
7.2.6 Other Drug Classes 99
8 Market Outlook 102
8.1 France 102
8.1.1 Forecast 102
8.1.2 Key Events 107
8.1.3 Drivers and Barriers 107
9 Appendix 110
9.1 Bibliography 110
9.2 Abbreviations 118
9.3 Methodology 120
9.4 Forecasting Methodology 120
9.4.1 Percent Drug-Treated Patients 120
9.4.2 Patient Warehousing 121
9.4.3 Drugs Included in Each Therapeutic Class 121
9.4.4 Launch and Patent Expiry Dates 122
9.4.5 General Pricing Assumptions 123
9.4.6 Individual Drug Assumptions 123
9.4.7 Generic Erosion 125
9.4.8 Selection of Pipeline Agents 125
9.4.9 Pricing of Pipeline Agents 126
9.5 Physicians and Specialists Included in this Study 129
9.6 Survey of Prescribing Physicians 131
9.7 About the Authors 132
9.7.1 Author 132
9.7.2 Global Head of Healthcare 132
9.8 About GlobalData 133
9.9 Contact Us 133
9.10 Disclaimer 133
List Of Tables
Table 1: Modes of HCV Transmission 16
Table 2: Symptoms of Acute and Chronic HCV Infection 17
Table 3: HCV Genotypes Present in the 9MM 19
Table 4: General Standard of Care by HCV Genotype 19
Table 5: Treatment Guidelines for HCV by Country 21
Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013 21
Table 7: Leading Treatments for HCV, 2012 25
Table 8: Product Profile – Incivek 27
Table 9: Efficacy of Incivek in Treatment-Naïve Patients (ADVANCE Trial) 27
Table 10: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial) 28
Table 11: Common Incivek Adverse Drug Reactions 29
Table 12: Incivek SWOT Analysis, 2012 30
Table 13: Product Profile – Victrelis 31
Table 14: Victrelis Efficacy in Treatment-Naïve Patients (SPRINT-2 Trial) 32
Table 15: Victrelis Efficacy in Treatment-Experienced Patients (RESPOND-2 Trial) 33
Table 16: Victrelis SWOT Analysis, 2012 34
Table 17: Product Profile – Pegasys 36
Table 18: Antiviral Efficacy of Peginterferon alfa-2a Compared with Interferon alfa-2b 37
Table 19: Pegasys SWOT Analysis, 2012 39
Table 20: Product Profile – PegIntron 41
Table 21: Antiviral Efficacy of Peginterferon alfa-2b Compared with Interferon alfa-2b 41
Table 22: PegIntron SWOT Analysis, 2012 43
Table 23: Effect of Addition of Ribavirin to Peginterferon HCV Therapy 45
Table 24: Ribavirin SWOT Analysis, 2012 46
Table 25: Summary of Minor Therapeutic Classes, 2012 46
Table 26: Overall Unmet Needs – Current Level of Attainment 47
Table 27: Clinical Unmet Needs – Gap Analysis, 2012 52
Table 28: HCV – Pipeline, 2012 56
Table 29: Comparison of Therapeutic Classes in Development for HCV, 2012 57
Table 30: Gilead’s Sofosbuvir Ongoing Clinical Trials of Interest 59
Table 31: Product Profile – Sofosbuvir 60
Table 32: Sofosbuvir’s Most Common Adverse Effects 63
Table 33: Sofosbuvir SWOT Analysis, 2012 67
Table 34: Janssen’s Simeprevir Ongoing Clinical Trials of Interest 69
Table 35: Product Profile – Simeprevir 70
Table 36: PILLAR Clinical Trial Results 70
Table 37: Adverse Events Observed in PILLAR Clinical Trial 71
Table 38: Simeprevir SWOT Analysis, 2012 75
Table 39: AbbVie’s Combination Therapy Ongoing Clinical Trials of Interest 77
Table 40: Product Profile – AbbVie Combination Therapy 78
Table 41: AVIATOR Clinical Trial Results 78
Table 42: AbbVie Combination Therapy SWOT Analysis, 2012 82
Table 43: Boehringer Ingelheim’s Faldaprevir Ongoing Clinical Trials of Interest 84
Table 44: Product Profile – Faldaprevir 85
Table 45: Efficacy of Interferon-Free Faldaprevir Regimen (SOUND-C2 Trial) 85
Table 46: Faldaprevir SWOT Analysis, 2012 90
Table 47: Bristol-Myers Squibb’s Daclatasvir Ongoing Clinical Trials of Interest 92
Table 48: Product Profile – Daclatasvir 93
Table 49: Efficacy of Daclatasvir in Treatment-Naïve Patients (COMMAND-1 Trial) 93
Table 50: Daclatasvir and Asunaprevir Quad Therapy Efficacy 94
Table 51: Daclatasvir Triple Therapy Adverse Events 95
Table 52: Daclatasvir SWOT Analysis, 2012 98
Table 53: Comparison of Peginterferon lambda with Peginterferon alfa (EMERGE Trial) 99
Table 54: Efficacy of Alisporivir in Treatment-Naïve HCV GT2/3 Patients (VITAL-1 Trial) 100
Table 55: Sales Forecasts ($m) for HCV in France, 2012–2022 105
Table 56: Key Events Impacting Sales for HCV in France, 2012 107
Table 57: French HCV Market – Drivers and Barriers, 2012 107
Table 58: Key Launch Dates 122
Table 59: Key Patent Expiries 122
Table 60: Physicians Surveyed, By Country 131
List Of Figures
Figure 1: HCV Genome and Polyprotein Composition 13
Figure 2: HCV Lifecycle Overview 14
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012–2022 56
Figure 4: Sales for HCV Therapeutics in France by Drug Class, 2012–2022 106
Global Hepatitis Partnering 2010 to 2016
Published: 01-May-2016 Price: US 1495 Onwards Pages: 150
"Delivery of this report will take 1-3 days after purchase."
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.
- Trends in partnering deals
- Top deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type
The report provides understanding and access to ......
United States Human Hepatitis B Immunoglobulin Industry 2016 Market Research Report
Published: 26-Apr-2016 Price: US 3800 Onwards Pages: 130
The United States Human Hepatitis B Immunoglobulin Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Human Hepatitis B Immunoglobulin industry.
The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Human Hepatitis B Immunoglobulin market analysis is provided for the United States markets including development trends, competitive landscape analys......
China Sofosbuvir Industry 2016 Market Research Report
Published: 22-Apr-2016 Price: US 3200 Onwards Pages: 135
The China Sofosbuvir Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Sofosbuvir industry.
The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Sofosbuvir market analysis is provided for the China markets including development trends, competitive landscape analysis, and key regions development status.
Development policies and pl......
Global Human Hepatitis B Immunoglobulin Industry 2016 Market Research Report
Published: 13-Apr-2016 Price: US 2800 Onwards Pages: 156
This is a professional and in-depth study on the current state of the Human Hepatitis B Immunoglobulin industry.
Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Human Hepatitis B Immunoglobulin market analysis is provided for the international market including development history, competitive landsca......
Europe Sofosbuvir Industry 2016 Market Research Report
Published: 15-Mar-2016 Price: US 3600 Onwards Pages: 135
This is a professional and in-depth study on the current state of the Sofosbuvir industry.
The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Sofosbuvir market analysis is provided for the Europe markets including development trends, competitive landscape analysis, and key regions development status.
United States Sofosbuvir Industry 2016 Market Research Report
Published: 07-Mar-2016 Price: US 3800 Onwards Pages: 134
This is a professional and in-depth study on the current state of the Sofosbuvir industry.
The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Sofosbuvir market analysis is provided for the United States markets including development trends, competitive landscape analysis, and key regions development status.
Hepatitis Drugs Markets in China
Published: 01-Mar-2016 Price: US 4000 Onwards Pages: 196
China's demand for Hepatitis Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, indust......
Global Sofosbuvir Consumption 2016 Market Research Report
Published: 01-Mar-2016 Price: US 4000 Onwards Pages: 171
This is a professional and in-depth study on the current state of the Sofosbuvir market.
First, the report provides a basic overview of the Sofosbuvir industry including definitions, classifications, applications and industry chain structure. And development policies and plans are discussed as well as manufacturing processes and cost structures.
Secondly, the report states the global Sofosbuvir market si......
Hepatitis Drugs Companies in China
Published: 01-Mar-2016 Price: US 1800 Onwards Pages: 63
This study focuses on China's Hepatitis Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions o......
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details - email@example.com
/ +1 888 391 5441 )
- Ad Hoc
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs